Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
2027. jan. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
2026. nov. 18.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
2026. nov. 4.· GeroScience· PUBMED
Publikáció
Discovery, optimization, and Phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist.
2026. nov. 3.· Molecular metabolism· PUBMED
Publikáció
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide.
2026. nov. 2.· Molecular pharmaceutics· PUBMED
Vizsgálat
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
2026. okt. 31.· PHASE4 · RECRUITING· CTGOV
Publikáció
Baseline depressive-symptom severity and divergent psychological trajectories during GIP and/or GLP-1 receptor agonist therapy: a prospective ecological momentary assessment study.
2026. okt. 31.· Diabetology international· PUBMED
Publikáció
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.
2026. okt. 31.· Diabetology international· PUBMED
Publikáció
Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.
2026. okt. 31.· Molecular metabolism· PUBMED
Vizsgálat
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
2026. okt. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.
2026. okt. 28.· Diabetes care· PUBMED
Publikáció
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.
2026. okt. 26.· Cell metabolism· PUBMED
Publikáció
Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.
2026. okt. 22.· Reviews in endocrine & metabolic disorders· PUBMED
Publikáció
Adverse oral effects of GLP-1 and GIP receptor agonists: a scoping review protocol.
2026. okt. 20.· BMJ open· PUBMED
Publikáció
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.
2026. okt. 16.· Frontiers in endocrinology· PUBMED
Publikáció
Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.
2026. okt. 13.· The Journal of clinical endocrinology and metabolism· PUBMED
Publikáció
The Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease.
2026. okt. 12.· Clinics in dermatology· PUBMED
Publikáció
Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.
2026. okt. 9.· Pharmaceutics· PUBMED
Publikáció
Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.
2026. okt. 9.· Metabolites· PUBMED
Publikáció
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
2026. okt. 8.· Cell metabolism· PUBMED
Publikáció
Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study.
2026. okt. 8.· Healthcare (Basel, Switzerland)· PUBMED
Vizsgálat
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
2026. okt. 7.· PHASE4 · RECRUITING· CTGOV
Publikáció
GLP-1 and Dual GLP-1/GIP Receptor Agonists in Lipedema: A Promising Therapeutic Option Requiring Rigorous Evaluation.
2026. okt. 7.· International journal of dermatology· PUBMED
Publikáció
US Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists.
2026. okt. 6.· Clinical and translational gastroenterology· PUBMED
Publikáció
Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.
2026. okt. 5.· Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir· PUBMED
Publikáció
Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.
2026. okt. 5.· Peptides· PUBMED
Publikáció
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
2026. okt. 1.· Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition· PUBMED
Publikáció
GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.
2026. szept. 30.· International journal of molecular sciences· PUBMED